Tfr2全缺失合并诱导性铁缺乏显著改善小鼠中间型地中海贫血表型
本研究在Tfr2Y245X/Y245X遗传性血色病与Hbbth3/+中间型β地中海贫血双突变小鼠中,用肝细胞特异性siRNA抑制Tmprss6。治疗诱导hepcidin表达,降低组织和血清铁,成熟红细胞增多,血红蛋白较未治疗β地中海贫血小鼠增加近50%。Tfr2突变单独治疗也升高hepcidin并降低总体铁负荷。
要点
- Tmprss6 siRNA治疗双突变小鼠诱导hepcidin并降低铁负荷。
- 治疗组血红蛋白较未治疗β地中海贫血小鼠增加近50%。
- 抑制Tmprss6联合靶向TFR2可能优于单抑制Tmprss6。
核心结论
- siRNA抑制Tmprss6联合靶向TFR2可能优于单抑制Tmprss6治疗中间型β地中海贫血的贫血和继发性铁过载。
- 该策略也可能用于抑制TFR2相关(3型)遗传性血色病的原发性铁过载。
研究设计与样本
- 研究在Tfr2Y245X/Y245X遗传性血色病与Hbbth3/+中间型β地中海贫血双突变小鼠中进行。
- 使用肝细胞特异性siRNA制剂抑制Tmprss6表达。
主要发现
- 治疗双突变小鼠诱导hepcidin并降低组织和血清铁水平。
- 治疗双突变动物产生更多成熟红细胞,血红蛋白较未治疗β地中海贫血小鼠增加近50%。
- 治疗Tfr2Y245X/Y245X血色病小鼠升高hepcidin表达并降低总体铁负荷。
临床怎么用
- 提示抑制Tmprss6联合靶向TFR2可能作为中间型β地中海贫血贫血和继发性铁过载的治疗策略。
- 提示该策略可能用于抑制TFR2相关(3型)遗传性血色病的原发性铁过载。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
β-thalassemias result from mutations in β-globin, causing ineffective erythropoiesis and secondary iron overload due to inappropriately low levels of the iron regulatory hormone hepcidin. Mutations in transferrin receptor 2 (TFR2) lead to hereditary hemochromatosis (HH) as a result of inappropriately increased iron uptake from the diet, also due to improperly regulated hepcidin. TFR2 is also thought to be required for efficient erythropoiesis through its interaction with the erythropoietin receptor in erythroid progenitors. Transmembrane serine protease 6 (TMPRSS6), a membrane serine protease expressed selectively in the liver, participates in regulating hepcidin production in response to iron stores by cleaving hemojuvelin (HJV). We have previously demonstrated that inhibiting TMPRSS6 expression with a hepatocyte-specific siRNA formulation, induces hepcidin, mitigates anemia, and reduces iron overload in murine models of β-thalassemia intermedia and HH. Here, we demonstrate that Tmprss6 siRNA treatment of double mutant Tfr2Y245X/Y245X HH Hbbth3/+ thalassemic mice induces hepcidin and diminishes tissue and serum iron levels. Importantly, treated double mutant animals produce more mature red blood cells and have a nearly 50% increase in hemoglobin compared to untreated β-thalassemic mice. Furthermore, we also show that treatment of Tfr2Y245X/Y245X HH mice leads to increased hepcidin expression and reduced total body iron burden. These data indicate that siRNA suppression of Tmprss6, in conjunction with the targeting of TFR2, may be superior to inhibiting Tmprss6 alone in the treatment of the anemia and secondary iron loading in β-thalassemia intermedia and may be useful as a method of suppressing the primary iron overload in TFR2-related (type 3) hereditary hemochromatosis.
引用
- Schmidt PJ, Fitzgerald K, Butler JS, et al. Global loss of Tfr2 with concomitant induced iron deficiency greatly ameliorates the phenotype of a murine thalassemia intermedia model. Am J Hematol. 2020. PMID: 33180328. doi:10.1002/ajh.26048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。